A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian,
fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162
and paclitaxel. Patients will receive increasing doses of study drug in combination with
paclitaxel in order to achieve the highest dose of study drug possible that will not cause
unacceptable side effects. Patients will be followed to see what side effects the combination
causes and what effectiveness the combination has, if any, in treating the cancer.
Approximately 36 patients from the US will be enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer